A carregar...
Regorafenib inhibited gastric cancer cells growth and invasion via CXCR4 activated Wnt pathway
AIM: Regorafenib is an oral small-molecule multi kinase inhibitor. Recently, several clinical trials have revealed that regorafenib has an anti-tumor activity in gastric cancer. However, only part of patients benefit from regorafenib, and the mechanisms of regorafenib’s anti-tumor effect need furthe...
Na minha lista:
| Publicado no: | PLoS One |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Public Library of Science
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5425213/ https://ncbi.nlm.nih.gov/pubmed/28489887 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0177335 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|